ERBB2 and breast carcinoma: In vitro studies indicate that HDIs have single-agent activity in HER2-overexpressing breast cancer cell lines including attenuation of HER2 expression, its tyrosine kinase activity, its cell membrane localisation and dimerisation with HER3 (Fuino et al, 2003; Bali et al, 2005).